Phase 1/2 study in unfit and frail transplant-ineligible patients with newly diagnosed myeloma: belantamab mafodotin plus lenalidomide and dexamethasone gave 97.6% response and 83.0% 18-month PFS in 42 patients at the recommended dose; median PFS not reached.
RCTn = 42
Terpos et al. Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma